Jonathan Gillis was named Chief Financial Officer of MapLight Therapeutics, Inc., effective June 18, 2026. As of November 6, 2026, MapLight Therapeutics, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 29, 2026 to June 18, 2026, naming 1 appointment and 1 departure (Form 8-K, June 18, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like MapLight Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
MapLight Therapeutics, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-29 to 2026-06-18. They name 2 people, with 1 appointment and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as MapLight Therapeutics, Inc. files it.
Also on the record for MapLight Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| September 18, 2026 | IPO filing, Form S-1/A | — | IPO filings | Source |
| September 9, 2026 | IPO filing, Form S-1 | — | IPO filings | Source |
| August 20, 2026 | Stake report, Schedule 13G, by Nan Fung Group Holdings Limited | 5.5% of the class | 5%+ stakes | Source |
| August 18, 2026 | Stake report, Schedule 13D/A, by Catalyst4, Inc. | 49.9% of the class | 5%+ stakes | Source |
| August 3, 2026 | Stake report, Schedule 13D/A, by Catalyst4, Inc. | 47.9% of the class | 5%+ stakes | Source |
| July 31, 2026 | Stake report, Schedule 13D/A, by Novo Holdings A/S | 4.9% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by T. Rowe Price Investment Management, Inc. | 7.4% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G, by Forbion Growth Opportunities Fund III Cooperatief U.A. | 7.1% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G, by T. Rowe Price Investment Management, Inc. | 6.2% of the class | 5%+ stakes | Source |
| November 20, 2025 | Stake report, Schedule 13D, by Catalyst4, Inc. | 45.1% of the class | 5%+ stakes | Source |
| November 4, 2025 | Stake report, Schedule 13D, by Novo Holdings A/S | 8.4% of the class | 5%+ stakes | Source |
| October 6, 2025 | IPO filing, Form S-1/A | — | IPO filings | Source |
Selling to them or working with them? See who runs MapLight Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on MapLight Therapeutics, Inc. and the records around it.
MapLight Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Form D filing Jul 2025
- Who owns it
Companies that share a holder
- Novo Holdings A/S also filed stake reports on 11 other companies: Avalyn Pharma Inc. (Aug 2026), Hemab Therapeutics Holdings, Inc. (Aug 2026), Obsidian Therapeutics, Inc. (Aug 2026)
- T. Rowe Price Investment Management, Inc. also filed stake reports on 167 other companies: CABALETTA BIO INC (Nov 2026), MADISON SQUARE GARDEN SPORTS CORP (Nov 2026), MSG RANGERS CORP (Nov 2026)
Watch MapLight Therapeutics, Inc.
Get an email when MapLight Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on MapLight Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on MapLight Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on MapLight Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 14 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-06-18 | In | Chief Financial Officer | 2026-06-18 | 8-K, 2026-06-18 | |
| 2026-04-29 | Out | 8-K, 2026-04-29 |
Who leads MapLight Therapeutics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Financial Officer: Jonathan Gillis, appointed, effective 2026-06-18 (filed 2026-06-18).
New leaders reset buying decisions — get the Full Report on MapLight Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Financial Officer at MapLight Therapeutics, Inc., with the record behind each one.
Find candidates like Chief Financial Officer at MapLight Therapeutics, Inc.Every change, in the filing's words
Appointed: Jonathan Gillis, Chief Financial Officer, effective 2026-06-18
In connection with the separation of Mr. Setia, the board of directors of the Company appointed Jonathan Gillis, the Company's Chief Administrative and Accounting Officer, as the Company's interim Chief Financial Officer and interim principal financial officer, effective June 18, 2026.
- On June 18, 2026, Vishwas Setia was separated as the Chief Financial Officer of MapLight Therapeutics, Inc. (the "Company"), effective immediately, following a review of a human resources violation.
- Mr. Setia's separation was wholly unrelated to the Company's financial or operating results, internal controls or clinical programs, or any concerns or disagreements regarding the Company's financial or reporting practices.
- Mr. Setia is not entitled to receive any severance payment in connection with his separation.
- However, the Company and Mr. Setia entered into a Separation Agreement on June 18, 2026, which contains (i) a release of claims against the Company and (ii) payment of continued health coverage for Mr. Setia and his dependents under COBRA for up to three months.
- Mr. Gillis will also continue his role as the Company's principal accounting officer.
Departing: Robert Malenka
On April 23, 2026, Robert Malenka, M.D., Ph.D., and Jim Trenkle, Ph.D., notified the Board of Directors (the "Board") of MapLight Therapeutics, Inc. (the "Company") of their respective decisions not to stand for reelection at the Company's Annual Meeting of Stockholders to be held on June 23, 2026.
- The Board has nominated Martin Babler and Troy Cox as Class I director nominees to replace Dr. Malenka and Dr. Trenkle.
- Dr. Malenka's and Dr. Trenkle's decisions not to stand for reelection were not due to any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
Tools for this story
Each opens in a new tab, filled in for MapLight Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.